ImmunityBio's "Worst Week" Is a 4% Dip in a 300% Winner — the Real Question Is How Much Lung Cancer Is Already Priced In

When a biotech's "worst week since July" is a roughly 4% decline, you're not reading about a selloff. You're reading about a stock that already had its move and is catching its breath. ImmunityBio (IBRX), the company behind the cancer immunotherapy Anktiva, is down about 4% on the week to around $8 a share — after roughly tripling over the past year, with a market value near $8 billion.

That gap between the headline and the tape is the first thing worth noticing. A 4% wobble in a stock that has tripled this year is profit-taking and repositioning, not the kind of panic that marks a low-risk entry. So what is the real story behind the news, and is the risk already on the table?

The story being sold this week

Two pieces of news put ImmunityBio in the headlights. A newly published patent application — listing founder Patrick Soon-Shiong as an inventor — lays out methods for using Anktiva to restore the immune cells that chemotherapy, radiation, and checkpoint inhibitors deplete, combining it with checkpoint inhibitors, cancer vaccines, and engineered NK cells. And the company is headed to the World Conference on Lung Cancer in Seoul this weekend, September 12–15, where the expansion case goes on display.

Both point at the same commercial prize. Anktiva is the first FDA-approved drug in its class — an IL-15 receptor agonist that stimulates natural killer cells and T cells — and it is approved in the U.S. today for a niche, early-stage bladder cancer. Lung cancer is a far larger market, and that is where the growth story lives. In a combined Phase 2 readout of 98 non-small cell lung cancer patients, those with milder lymphopenia — less severe immune-cell depletion — had median survival of 21.1 months versus 11.5 months for those with severe depletion. The thesis, in plain terms: keep the immune system working, and the other cancer treatments keep working longer.

The first global lung cancer approval came in Saudi Arabia in January. The U.S. is not there yet; the lung cancer program is running in randomized Phase 3 trials, with data and regulatory decisions still ahead.

What's underneath the story

The commercial momentum is real but small. Anktiva brought in $113 million of net product revenue for all of 2025, up about 700% year over year, and on the order of $51 million in the most recent quarter, roughly double a year earlier. Against a market value near $8 billion, that is a price-to-sales ratio in the neighborhood of 50 times. And the business loses money — a $351 million net loss in 2025, with cash burn in the same general range.

That is the crux. This is not a beaten-down valuation discounting a doomsday scenario; it is a valuation that already pays for a successful expansion into lung cancer. The new patent and the Seoul conference do not change the economics — they extend a thesis the market has been paying for all year.

The honest test

For a buyer of distressed growth, the usual question is whether the market misread the risk. Here the market has not misjudged on the downside — if anything, the risk runs the other way, into the optimism. A 4% week and a bearish retail-sentiment tag are positioning notes sitting on top of a tripled stock, not evidence of selling exhaustion. On the tests I lean on — fundamental quality, valuation versus growth, and the durability of the moat — the picture is in tension: the product is real and the moat is plausible (a novel mechanism, patent protection laid out to well beyond 2035), but the share price is not discounting the work that is still unproven in the U.S.

If the lung cancer thesis is one you already hold, that is a view with a long window, and the stock has given back part of its run from the highs — that may be an entry you find acceptable. But if a headline about a "worst week" is what is pulling you in, that is the wrong reason to be here. The watch items that actually change the economics are the lung cancer Phase 3 data, the U.S. regulatory path, and an FDA decision on a broader bladder label due by January 6, 2027. Those will tell you whether Anktiva's expansion is worth the price — a 4% dip in a stock that has tripled will not.